Catalyst pharmaceuticals, inc. (CPRX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating Activities:
Net income (loss)

31,875

-34,003

-18,412

-18,072

-20,232

-15,509

-12,154

-4,076

-6,391

-4,006

-7,241

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation

54

37

45

43

34

26

22

10

42

25

30

Amortization of right-of-use asset

243

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

3,824

3,550

2,407

1,836

1,585

777

175

340

416

450

601

Change in accrued interest and accretion of discount on investments

290

443

186

-886

-65

993

1,890

-1,129

-319

-

-

(Increase) decrease in:
Accounts receivable, net

10,536

-

-

-

-

-

-

-

-

-

-

Inventory

1,900

56

-

-

-

-

-

-

-

-

-

Interest receivable

-

-

-

-

-

-

-

-

-

-

-12

Government grant receivable

-

-

-

-

-

-

-

-

-134

134

-

Prepaid expenses and other current assets and deposits

2,701

476

125

-456

452

2,943

299

1,110

31

58

-39

Increase (decrease) in:
Accounts payable

1,780

391

1,012

-860

-20

963

-514

1,101

158

-143

-83

Accrued expenses and other liabilities

12,540

4,850

1,142

-480

1,134

2,748

1,005

-276

365

108

-1,041

Operating lease liability

276

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

34,611

-26,147

-13,742

-17,963

-18,015

-12,941

-9,875

-5,140

-4,985

-3,757

-7,683

Investing Activities:
Purchases of property and equipment

19

92

-

96

23

57

9

52

3

2

2

Purchases of investments

34,725

36,790

3

68

-18

8,979

9,978

7,504

-

-

-

Proceeds from maturities and sales of investments

71,969

21,800

-

3,717

-1

296

2,491

-6,502

-

-

-

Net cash provided by (used in) investing activities

37,224

-15,082

-3

3,552

-6

-8,741

-7,496

-14,059

-3

-2

-2

Financing Activities:
Proceeds from issuance of common stock, net

-

-

53,772

-

34,873

26,725

14,071

9,564

5,542

1,456

3,698

Payment of employee withholding tax related to stock-based compensation

0

4

-

11

-

-

-

-

-

-

-

Proceeds from issuance of convertible promissory note

-

-

-

-

-

-

-

5,000

-

-

-

Proceeds from exercise of warrants

-

-

3,209

-

1,895

1,316

4,083

16

-

-

-

Proceeds from exercise of stock options

1,116

297

368

80

390

522

23

-

-

-

-

Net cash provided by (used in) financing activities

1,116

293

57,350

68

37,159

28,563

18,178

14,580

5,542

1,456

3,698

Net increase (decrease) in cash and cash equivalents

72,952

-40,937

43,603

-14,341

19,138

6,880

806

-4,619

553

-2,304

-3,987

Non-cash investing and financing activities:
Unrealized gain (loss) on available-for-sale securities

29

-20

-

-

-

-

-

-

-

-

-

Exercise of liability classified warrants for common stock

-

-

309

-

1,721

18

569

16

-

-

-

Non-cash incentive received from lessor

-

-

-

-

131

-

-

-

-

-

-

Conversion of note to common stock

-

-

-

-

-

-

-

5,000

-

-

-